Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 9/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 8/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 8/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 7/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.51 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180196 | 0.98 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Bromide SCHEMBL28009101 | 0.94 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Bromide SCHEMBL9702931 | 0.88 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL28520045 | 0.76 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12814059 | 0.76 | MAPT (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29553211 | 0.76 | MAPT (0.52) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL25001636 | 0.72 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL31330119 | 0.72 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL22977483 | 0.72 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL22025603 | 0.72 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161300-A1 | COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADS THERAPEUTICS LLC | 2025-05-22 | — | — | US | disclosed |
| US-12156873-B2 | Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same | ADS THERAPEUTICS LLC (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3813793-B1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADS THERAPEUTICS LLC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11179388-B2 | Topical composition for treating rosacea and a method for treating rosacea with the same | ADS THERAPEUTICS LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210228574-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADS THERAPEUTICS LLC | 2021-07-29 | — | — | US | disclosed |
| EP-3813793-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | Cloudbreak Therapeutics, LLC (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112165934-A | Compositions and methods for treating ocular congestion | 克劳德布雷克医疗有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-2815748-B1 | Compounds, formulations, and methods for treating or preventing rosacea | GALDERMA PHARMA SA (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20200121675-A1 | A TOPICAL COMPOSITION FOR TREATING ROSACEA AND A METHOD FOR TREATING ROSACEA WITH THE SAME | ADS THERAPEUTICS LLC | 2020-04-23 | — | — | US | disclosed |
| EP-3630161-A1 | A TOPICAL COMPOSITION FOR TREATING ROSACEA AND A METHOD FOR TREATING ROSACEA WITH THE SAME | Whitcup, Scott (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-0422878-B1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN INC (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5300504-A | Increasing renal fluid flow | ALLERGAN, INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5231096-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| WO-1993013771-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5204347-A | Reduction in intraocular pressure; increase renal flow; alteration in the rate of fluid transport in the gastrointestinal tract | ALLERGAN, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| WO-1992013855-A1 | (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5077292-A | Gastrointestinal disordes; kidney and vision defects | ALLERGAN, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| US-5021416-A | Glaucoma | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121675-A1 | A TOPICAL COMPOSITION FOR TREATING ROSACEA AND A METHOD FOR TREATING ROSACEA WITH THE SAME | TIE1, FGF2, EGFR | ADRA2A 358/4885ADRA2B 592/4885ADRA2C 816/4885 |
| US-20250161300-A1 | COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADRB1, ADRB2, ADRB3 | ADRA2A 5/4885ADRA2B 6/4885ADRA2C 15/4885 |
| US-12156873-B2 | Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same | ADRB1, ADRB2, ADRB3 | ADRA2A 5/4885ADRA2B 6/4885ADRA2C 16/4885 |
| US-20210228574-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADRB1, ADRB2, ADRA1A | ADRA2A 4/4885ADRA2B 6/4885ADRA2C 10/4885 |
| US-11179388-B2 | Topical composition for treating rosacea and a method for treating rosacea with the same | TIE1, EGFR, FGF2 | ADRA2A 394/4885ADRA2B 675/4885ADRA2C 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.